ERBB2 and breast neoplasm: In summary, we have been able to successfully develop a PBPK-PD model of MBQ-167 in mice that accurately characterizes: (i) the pharmacokinetic properties of MBQ-167 in different mouse tissues, (ii) the dynamics of tumor progression, and (iii) the anti-tumor effect of MBQ-167 in HER2+ and Triple Negative breast tumors following intraperitoneal administration.